Core Viewpoint - Acadia Pharmaceuticals has experienced a decline in share price by approximately 12.9% since its last earnings report, underperforming the S&P 500, raising questions about its future performance leading up to the next earnings release [1]. Financial Performance - In Q4 2025, Acadia reported earnings per share (EPS) of 16 cents, exceeding the Zacks Consensus Estimate of 12 cents, but down from 17 cents in the same quarter the previous year [2]. - Total revenues for Q4 2025 were $284 million, falling short of the Zacks Consensus Estimate of $293 million, but reflecting a 9% year-over-year increase driven by Daybue and Nuplazid [3]. - Nuplazid revenues increased by 7% year-over-year to $174.4 million, although it missed the consensus estimate of $184.1 million [4]. - Daybue achieved net product sales of $109.6 million in Q4 2025, a 13% year-over-year increase, slightly surpassing the consensus estimate of $108.4 million [4]. - For the full year 2025, Acadia's total revenues reached $1.07 billion, a 12% increase year-over-year, but below the consensus estimate of $1.08 billion [7]. Expenses and Cash Position - Research and development (R&D) expenses were $84.8 million, down 16% year-over-year, while selling, general and administrative (SG&A) expenses rose by 20% to $155.6 million due to increased marketing investments [5]. - As of December 31, 2025, Acadia had cash, cash equivalents, and investments totaling $820 million, a decrease from $847 million as of September 30, 2025 [6]. Future Outlook - For 2026, Acadia anticipates total revenues from U.S. sales to be between $1.22 billion and $1.28 billion, with Nuplazid sales projected at $760 million to $790 million and Daybue sales expected to be between $460 million and $490 million [8]. - R&D expenses for 2026 are projected to be between $385 million and $410 million, while SG&A expenses are expected to range from $660 million to $700 million [8]. Market Sentiment - Recent estimates for Acadia have trended downward, with a significant shift of -60.94% in consensus estimates over the past month [9]. - Acadia currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [11]. - The company has a subpar Growth Score of D and a Momentum Score of F, with an aggregate VGM Score of F, suggesting challenges in multiple investment strategies [10].

Core Viewpoint - Acadia Pharmaceuticals faces a regulatory setback as the European Medicines Agency's CHMP has issued a negative opinion against the approval of trofinetide for treating Rett syndrome in the EU [1][6]. Regulatory Developments - The negative opinion from CHMP was anticipated following an early February notification of a negative trend vote on the marketing application for trofinetide [2]. - Acadia plans to request a re-examination of the CHMP's decision after reviewing the grounds for refusal [2][6]. Clinical Study Insights - The pivotal LAVENDER study met its co-primary and key secondary endpoints; however, CHMP cited limitations such as the modest treatment effect after 12 weeks and incomplete capture of core symptoms of Rett syndrome [3][6]. - Concerns were raised regarding the assessment of long-term outcomes due to patient discontinuations over time [3]. Market Context - Rett syndrome is a rare neurodevelopmental disorder affecting approximately one in 10,000-15,000 female births globally [4]. - The FDA approved trofinetide as the first and only treatment for Rett syndrome in the U.S. in 2023, marketed as Daybue [5]. Financial Outlook - Despite the regulatory hurdle, Acadia is positioned for long-term growth, expecting combined net sales of around $1.7 billion by 2028, with $1 billion from Nuplazid and $700 million from Daybue [7]. - Nuplazid, the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, recorded $680.1 million in sales in 2025, reflecting a 12% year-over-year increase [8]. - Daybue has also shown promising sales uptake, with $391.4 million in sales in 2025, marking a 12% year-over-year growth [9]. Product Developments - The FDA approved Daybue Stix, a new formulation of trofinetide, for oral solution in late 2025, expanding the Daybue franchise [10]. - Acadia plans a limited launch of Daybue Stix in Q1 2026, with broader availability expected in Q2 [11][13].

Summary of ACADIA Pharmaceuticals FY Conference Call Company Overview - **Company**: ACADIA Pharmaceuticals (NasdaqGS:ACAD) - **Date of Conference**: March 02, 2026 Key Financial Projections - **Revenue Guidance for 2028**: Projected net sales of **$1.7 billion** - **NUPLAZID**: $1 billion - **Daybue**: $700 million - **Growth Rate for NUPLAZID**: Expected **12% growth** in 2026 and similar in 2027 - **Growth Rate for Daybue**: Expected **20% growth** in the current year [7][13][15] Product Performance and Strategies NUPLAZID - **Fourth Quarter Growth**: Reported **18% growth** in MBRXs (monthly active patients) [13] - **Marketing Strategy**: Focused on direct consumer campaigns and an expanded field force, increasing targets from **7,000 to 11,000 physicians** [13][21] - **Field Force Expansion**: Increased by **30%**, expected to impact growth in the latter half of the year [13][14] Daybue - **Current Market Penetration**: Approximately **27%** in the community setting, expected to rise to the early **30s** by year-end [15][198] - **New Product Launch**: DAYBUE STIX, a new formulation aimed at improving patient adherence and flexibility [15][16] - **Expected Incremental Patients**: Approximately **400 additional patients** expected to be unlocked through the new formulation by 2028 [212] Pipeline Developments Remlifanserin (204) - **Phase 2 Data Timeline**: Expected between **August and October** [37] - **Study Design**: Focused on Alzheimer's disease psychosis with a primary endpoint of SAPS H&D at week 6 [51][52] - **Patient Population**: Enrolling around **300 patients** [53] Clinical Rationale - **Biological Rationale**: Targeting serotonin signaling disruption in Lewy body dementia and Alzheimer's disease psychosis [182] - **Clinical Evidence**: Previous studies with pimavanserin support the mechanism for remlifanserin [183][194] Regulatory and Market Challenges - **CHMP Negative Opinion**: Received a negative trend vote regarding Daybue, citing concerns over the clinical meaningfulness of endpoints [225][226] - **Reexamination Process**: Plans to apply for reexamination within the next few weeks, with a timeline of about **120 days** for review and decision [257][258] Other Pipeline Programs ACP-211 - **Differentiation from IV Ketamine**: ACP-211 is orally bioavailable and aims to provide a better patient experience with lower dissociation levels [275] - **Phase 2 Study Design**: Double-blind, randomized, placebo-controlled trial with a primary endpoint of MADRS scale at 4 weeks [288][289] Conclusion - ACADIA Pharmaceuticals is positioning itself for significant growth through its existing products and pipeline developments, while navigating regulatory challenges and expanding its market reach through innovative formulations and strategic marketing efforts.

Core Insights - The Federal Reserve's shift from higher interest rates to potential rate cuts is expected to benefit mid-cap stocks, creating a favorable environment for growth and M&A activity in 2026 [2] - Mid-cap stocks are currently trading at a historically wide 28% discount due to years of investor preference for large- and small-cap stocks [2] - Market leadership is expanding beyond mega-cap tech, with improved earnings revisions in mid- and small-cap sectors [4] Mid-Cap Stock Analysis - Establishment Labs Holdings Inc. (NASDAQ:ESTA) reported $64.62 million in Q4 revenue, slightly above the consensus expectation of $64.12 million, driven by strong demand and market acceptance of its Preserve product [11][12] - ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) achieved GAAP revenues of $284 million for Q4 and $1.07 billion for the entire year, reflecting annual increases of 9% and 12% respectively [17] - ACAD's NUPLAZID and DAYBUE products are projected to generate significant sales, with full-year 2026 revenue forecasted between $1.22 billion and $1.28 billion [18]

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

Core Insights - Acadia Pharmaceuticals anticipates a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its marketing application for trofinetide to treat Rett syndrome [1][2] Company Overview - Acadia was informed of a negative trend vote on its marketing application for trofinetide, which may delay potential approval in the European Union [2] - The company plans to seek a re-examination of the CHMP opinion once it is formally adopted [2] Product Information - Trofinetide is intended for treating Rett syndrome, a rare neurodevelopmental disorder affecting approximately one in 10,000-15,000 female births globally [3] - The FDA approved trofinetide for treating Rett syndrome in adults and pediatric patients aged two years and older in 2023, marketed as Daybue in the United States [4] Financial Performance - Acadia's shares have increased by 8.6% over the past six months, while the industry has seen a rally of 18.8% [5] - The company expects long-term growth from its products Nuplazid and Daybue, targeting combined net sales of $1.7 billion by 2028, with approximately $1 billion from Nuplazid and $700 million from Daybue [8][9] Market Position - Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, with patent protection until 2038 [10] - In the first nine months of 2025, Nuplazid generated $505.7 million in sales, reflecting a 13% year-over-year increase [10] - Daybue has also shown promising sales, with $281.8 million in sales during the first nine months of 2025, up 12% year-over-year [11] New Product Launch - The FDA recently approved Daybue Stix, an oral solution for treating Rett syndrome, which will be launched in a limited capacity in Q1 2026, followed by broader availability in Q2 2026 [12][13]

Core Insights - The article provides an analysis of a specific company, focusing on its financial performance and market position, but does not offer exhaustive details or personalized investment advice [2][3] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15%, reaching $1.5 billion in the last quarter [2] - Operating income also saw a rise, increasing by 10% to $300 million, indicating improved operational efficiency [2] Market Position - The company has strengthened its market share, now holding 25% of the industry, up from 22% last year, reflecting successful strategic initiatives [2] - Competitive analysis shows that the company is outperforming its main rivals, which have only seen a 5% growth in the same period [2] Future Outlook - Analysts project continued growth for the company, with expectations of a 12% increase in revenue for the next fiscal year, driven by new product launches and market expansion [2] - The company is also exploring potential mergers and acquisitions to further enhance its market presence and capabilities [2]

Financial Data and Key Metrics Changes - The company expects over $1 billion in sales from its two commercial products, Nuplazid and Daybue, for the current year [4] - The guidance for Nuplazid sales has been narrowed to $685-$695 million, reflecting an upward adjustment [24][26] - The company maintains a strong balance sheet with over $800 million in cash and no debt, indicating a solid financial position for future investments [5][108] Business Line Data and Key Metrics Changes - Nuplazid has seen a 20% increase in both referrals and new patient starts, marking the strongest quarter in new patient starts in a long time [10] - Daybue has experienced significant increases in new referrals, the largest since Q3 2024, indicating positive momentum from recent investments [12] Market Data and Key Metrics Changes - The company is expanding its commercial footprint in the U.S. and plans to enter the European market with expected approval next year [12][59] - The market for Alzheimer's disease psychosis (ADP) is significantly larger than that for Parkinson's disease psychosis (PDP), presenting a substantial growth opportunity [73] Company Strategy and Development Direction - The company is focused on expanding its sales force and enhancing marketing efforts for both Nuplazid and Daybue to drive growth [11][45] - The strategy includes leveraging existing data and insights to optimize targeting and positioning of the sales force for Nuplazid [16] - The company plans to market Daybue independently in Europe, building a team to support this initiative [58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued meaningful growth for both franchises, with plans to provide guidance for Nuplazid next year [31] - The company is mindful of potential impacts from legislative changes but does not anticipate significant disruptions to profitability [36][37] - Management highlighted the importance of ongoing investments in R&D and commercial operations to support long-term growth [110] Other Important Information - The company has a robust pipeline, with ACP-204 being a key focus for upcoming trials in Alzheimer's disease psychosis and Lewy body dementia psychosis [5][66] - Management emphasized the importance of patient retention and the ongoing benefits of Daybue for patients who remain on therapy [48] Q&A Session Summary Question: Can you summarize the commercial performance for Nuplazid and Daybue? - Management noted strong growth for both products, with Nuplazid seeing a significant increase in new patient starts and Daybue benefiting from expanded commercial efforts [10][12] Question: What is the guidance for Nuplazid sales this year? - The guidance has been narrowed to $685-$695 million, reflecting an upward adjustment from previous estimates [24][26] Question: How does the IRA negotiations impact the company? - Management indicated that while there may be some price decreases in the future, the business will remain profitable and capable of supporting growth initiatives [36][37] Question: What is the strategy for marketing Daybue in Europe? - The company plans to market Daybue independently in Europe, starting with Germany, and has begun building a team to support this effort [58][59] Question: What are the expectations for the upcoming trials for ACP-204? - Management expressed excitement about the phase 2 readout for ACP-204 in Alzheimer's disease psychosis, viewing it as a higher probability of success due to existing data [66][72]

Financial Data and Key Metrics Changes - The company expects over $1 billion in sales from its two commercial products, Nuplazid and Daybue, for the current year [5] - The guidance for Nuplazid has been narrowed to $685-$695 million, reflecting an upward shift from previous estimates [24][26] - The company maintains a strong balance sheet with over $800 million in cash and no debt, indicating a solid financial position for future investments [6][116] Business Line Data and Key Metrics Changes - Nuplazid has seen a 20% increase in both referrals and new patient starts, marking the strongest quarter in new patient starts in a long time [10] - Daybue has experienced significant increases in new referrals, the largest since the third quarter of 2024, indicating positive momentum from recent investments [12] Market Data and Key Metrics Changes - The company is expanding its commercial footprint in the U.S. and plans to enter the European market with expected approval next year [12][60] - The market for Alzheimer's disease psychosis (ADP) is significantly larger than that for Parkinson's disease psychosis (PDP), presenting a substantial growth opportunity [76] Company Strategy and Development Direction - The company is focused on expanding its customer-facing field force to enhance growth and profitability for Nuplazid [11] - There is a strategic emphasis on leveraging existing data and experience to optimize the development of ACP-204, a next-generation treatment for ADP and Lewy body dementia psychosis [67][75] - The company plans to market Daybue independently in Europe, building a team to facilitate this expansion [60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued meaningful growth for both Nuplazid and Daybue, with expectations for further guidance on peak sales for Nuplazid next year [33] - The potential impact of the Inflation Reduction Act (IRA) on pricing and profitability is acknowledged, but management believes the business will remain profitable despite anticipated price decreases [39] Other Important Information - The company has a robust pipeline with several important catalysts, including the phase 2 readout for ACP-204 expected mid-next year [6][68] - Management highlighted the importance of educating physicians about the benefits and side effects of Daybue to improve patient retention on therapy [57] Q&A Session Summary Question: What is the guidance for Nuplazid this year? - The guidance for Nuplazid is set at $685-$695 million, reflecting an upward adjustment from previous estimates [24][26] Question: How does the company plan to expand its market presence? - The company plans to expand its commercial footprint in the U.S. and enter the European market, with a focus on building a dedicated team for marketing Daybue [60] Question: What are the expectations for the upcoming phase 2 readout for ACP-204? - The phase 2 readout for ACP-204 is anticipated mid-next year, with management expressing excitement about the potential for success based on existing data [68][82]

Financial Data and Key Metrics Changes - The company reported total revenues of $278.6 million for Q3 2025, an increase of 11% year-over-year [4][21] - Debut achieved net sales of $101.1 million, also up 11% year-over-year, attributed entirely to volume growth [21] - Nuplazid delivered net sales of $177.5 million, marking a 12% year-over-year growth, with 9% of that growth coming from volume [11][21] - R&D expenses rose to $87.8 million from $66.6 million year-over-year, primarily due to higher clinical trial expenses [21] - SG&A expenses remained flat at $133.4 million compared to the previous year [21] - The company ended the quarter with $847 million in cash, up from $762 million at the end of Q2 2025 [22] Business Line Data and Key Metrics Changes - Debut generated $101.1 million in net sales, with the highest prescription volume since its launch, reaching over 1,000 unique patients globally [5][7] - Nuplazid's net sales of $177.5 million represented the strongest sales quarter ever, with a 21% increase in referrals year-over-year [11][12] - The number of unique prescribers for Debut increased to 956, with community-based physicians accounting for 74% of new prescriptions [8][9] Market Data and Key Metrics Changes - Market penetration for Debut remains low at approximately 40% in the U.S. and 27% in community settings, indicating significant growth opportunities [9] - The U.S. PDP market represents a substantial opportunity, with around 1 million Parkinson's patients, half of whom may experience hallucinations and delusions [12][13] Company Strategy and Development Direction - The company is making strategic investments in expanding its salesforce by 30% starting in Q1 2026 to capture growth opportunities for Nuplazid [14][30] - The focus is on advancing the pipeline of novel product candidates, with recent phase two and phase three trials initiated [6][16] - The company aims to achieve over $1 billion in total revenues by the end of 2025, positioning itself for continued growth into 2026 and beyond [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability and growth trajectory driven by new sales teams for Debut, with strong patient engagement metrics [24] - The company anticipates continued growth in patient counts through Q4 2025 and into 2026, supported by the expansion of its field force [44] - Management highlighted the importance of real-world evidence in discussions with European payers to ensure the value of Debut is recognized [91] Other Important Information - The company is actively pursuing international expansion efforts, with ongoing regulatory processes in the EU for terfenatide and successful initiation of phase three studies in Japan [18][19] - The company remains committed to advancing its robust pipeline, with multiple programs progressing through key stages of development [19] Q&A Session Summary Question: How is the expanded New Plasid client-facing force organized? - The expansion focuses on both newly activated prescribers and community versus long-term care facilities, with growth seen across all channels [27][30] Question: What is the expected clinically meaningful score on the SAPS HD score for ACP204? - The company is looking for a moderate effect size of 0.4 on SAPS HD, which is deemed appropriate for the patient population [33][36] Question: How will the company ensure quick script uptake after a potential positive CHMP opinion for Debut? - The company is preparing for launch readiness in Europe, starting with Germany, and has already opened compassionate use programs in multiple countries [63][65] Question: What are the drivers behind the higher average net selling price for New Plasid? - The pricing is aligned with inflation rates, primarily due to the majority of sales being for Medicare-based patients [58][60] Question: Why is now the right time to add to the field force for New Plasid? - The decision is based on observed momentum in referrals and the need to capitalize on new prescribers outside the core target base [80][82]